14,466 Shares in Kenvue Inc. $KVUE Purchased by Ontario Teachers Pension Plan Board

Ontario Teachers Pension Plan Board purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, Holdings Channel reports. The fund purchased 14,466 shares of the company’s stock, valued at approximately $303,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Kenvue by 4.9% during the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock worth $5,494,882,000 after buying an additional 10,600,682 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Kenvue by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock worth $1,021,267,000 after acquiring an additional 604,953 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Kenvue by 2.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 25,606,238 shares of the company’s stock worth $613,882,000 after acquiring an additional 633,461 shares during the last quarter. Boston Partners increased its holdings in Kenvue by 7.4% during the 1st quarter. Boston Partners now owns 25,346,453 shares of the company’s stock valued at $606,920,000 after purchasing an additional 1,750,490 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Kenvue by 11.6% in the 1st quarter. JPMorgan Chase & Co. now owns 24,912,226 shares of the company’s stock valued at $597,395,000 after purchasing an additional 2,597,920 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Kenvue stock opened at $16.27 on Tuesday. The company has a market cap of $31.17 billion, a PE ratio of 21.70, a PEG ratio of 2.43 and a beta of 0.71. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $25.17. The company’s 50-day moving average is $16.37 and its two-hundred day moving average is $19.98.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The company had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. During the same quarter in the previous year, the company earned $0.28 EPS. Kenvue’s revenue was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th will be given a dividend of $0.2075 per share. The ex-dividend date is Wednesday, November 12th. This represents a $0.83 annualized dividend and a dividend yield of 5.1%. Kenvue’s payout ratio is presently 110.67%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on KVUE shares. Johnson Rice restated a “neutral” rating on shares of Kenvue in a report on Tuesday, October 28th. Deutsche Bank Aktiengesellschaft set a $18.00 price target on shares of Kenvue in a research report on Friday, October 24th. Bank of America lowered their price objective on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, October 8th. Edward Jones downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Finally, Royal Bank Of Canada decreased their price target on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and a consensus target price of $20.23.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.